Previous Article | Next Article ![]()
Journal of Bacteriology, June 2002, p. 3126-3129, Vol. 184, No. 11
0021-9193/02/$04.00+0 DOI: 10.1128/JB.184.11.3126-3129.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Program in Molecular and Cell Biology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104
Received 22 January 2002/ Accepted 1 March 2002
|
|
|---|
|
|
|---|
![]() View larger version (43K): [in a new window] |
FIG. 1. Alignment of VirB7 encoded by the A. tumefaciens T plasmid and TraV encoded by F plasmid. The sequences begin with the N-terminal cysteine characteristic of outer membrane lipoproteins; leader peptide sequences have been omitted. All cysteines are indicated by dark shading, and two other identical residues are indicated by light shading. Accession numbers or references are as follows: for VirB7 from pTiAB2/73, AF329849; for VirB7 from pTiA6NC, J03216; for VirB7 from pTiC58, X53264; for TraV from F plasmid, Frost et al. (6); for TraV from R100, NP_052954; and for TraV from pSLT, NP_490570.
|
TraV also contains internal cysteines (Fig. 1). One is at the same position relative to the N-terminal cysteine of the mature protein as the C10 of VirB7 is, and the other is 8 residues beyond, at position 18. We have examined the role of these internal cysteines in the function, accumulation, and localization of TraV.
We first mutated each cysteine in TraV to a serine. Mutant traV genes were synthesized by oligonucleotide-directed mutagenesis with three primers. In this method, two outside primers encompassing the entire traV sequence and encoding appropriate restriction sites were added at the usual concentration to three amplification PCR mixtures. The forward primer [GTGAACTGC(G
A)GATGAGAAAGG] corresponded to tra coordinates 6665 to 6684 (6); the G
A transition introduced a PstI site. The reverse primer [GGCTGATATA(C
G)AACTTCAGGGC] corresponded to tra coordinates 7234 to 7213; the C
G transition and deletion of a C (subscript) introduced an EcoRI site. A third, mutagenic primer was also added but in limiting amounts, usually 0.1, 0.2, and 0.4 mol/mol of outside primer. The mutagenic primers were GAATTTGAGT(G
C)TAACGCCACC for C10S and CCGATACCT(G
C)TATGACGATGG for C18S. After 30 cycles of amplification, the reaction products were combined, digested with PstI and EcoRI, and cloned into pUC19. Random transformants were then sequenced; the frequency of mutants was 10 to 50%. The traV double mutant was synthesized from traVC18S in a second PCR. The respective pUC19 traV derivatives were transformed into Escherichia coli strain RD17/pOX38 traV::cat. The traV::cat allele was constructed essentially as described previously (8). For functional assays, cells, including recipient cells for mating experiments, were routinely grown with aeration to optical densities (at 600 nm) of 0.3 to 0.6 in nutrient broth (1% tryptone, 0.1% yeast extract, 0.08% NaCl, 0.2% glucose, 5 mM concentrations each of MgCl2 and CaCl2). For cell fractionation experiments, cells were grown in Luria-Bertani broth to optical densities of 0.6 to 0.8. All cultures were grown in the absence of IPTG (isopropyl-ß-D-thiogalactopyranoside). Without induction, TraV protein levels in cells containing pUC19 traV plasmids were shown by Western blot analysis to be similar to those observed in RD17/pOX38 tra+ cells.
We carried out four functional assays which determined the following characteristics: DNA donor activity (1); transduction to kanamycin resistance by donor-specific, filamentous bacteriophage M13K07 (1, 14); sensitivity to RNA bacteriophage R17 by plaque assay; and sensitivity to M13K07 by plaque assay. In all assays, the wild-type traV gene fully complemented the pOX38 traV::cat allele; this required increases in donor activity and bacteriophage sensitivity of at least 6 to 7 orders of magnitude (Table 1). The traVC10S allele likewise complemented the pOX38 traV mutation to a level that was within the same order of magnitude as wild-type traV. This observation, along with the data shown below, establishes that C10 of TraV and C10 of VirB7 have very different effects on the function and stability of the respective lipoproteins.
|
View this table: [in a new window] |
TABLE 1. Effect of traV cysteine mutations on biological functions
|
The double mutant also complemented the traV::cat allele for DNA donor activity, though perhaps not quite fully. However, the double mutant was even less active as a host for the M13K07 transducing bacteriophage than the traVC18S strain. Surprisingly, this failure to complement fully was not as evident in a plaque assay on solid medium; by this test, the traVC10S/C18S plasmid restored the sensitivities of both M13K07 and R17 to near normal levels. In summary, it does not appear that the internal cysteines of TraV are absolutely required for any of the functions associated with the role of TraV in F-pilus assembly and function. The data do not exclude the possibility that these cysteines play an as-yet-unidentified role in sensitivity to donor-specific DNA bacteriophage, at least under some conditions.
From the data in Table 1, we were able to infer that all of the TraV proteins should accumulate in the outer membrane of the cell. Western blot analysis (7) of purified outer membrane fractions confirmed this prediction (Fig. 2A). However, while TraV could be detected in outer membrane preparations from all four strains, TraV from the traVC18S strain contained the least amount. Moreover, the smudge that is visible below the TraVC18S band, but not, or to a lesser degree, beneath the other TraV bands, suggests that one reason for this quantitative difference is that TraVC18S is degraded. Hence, TraV C18 might contribute to TraV stability.
![]() View larger version (102K): [in a new window] |
FIG. 2. Accumulation of TraV proteins in the outer membrane. (A) Standard (reducing) gel; (B) nonreducing gel. Outer membrane fractions were obtained by banding in sucrose density gradients as described previously (9). Gels contained 4 to 20% polyacrylamide gradients. For nonreducing gels, mercaptoethanol was omitted from the sample buffer. Lanes 1, outer membrane from pOX38 traV::cat/pUC traV (wild-type) cells; lanes 2, outer membrane from pOX38 traV::cat/pUC traVC10S cells; lanes 3, outer membrane from pOX38 traV::cat/pUC traVC18S cells; lanes 4, outer membrane from pOX38 traV::cat/pUC traVC10S/C18S cells. The caret at the left of panel A indicates the TraV protein. The carets in panel B indicate possible TraV dimers. Numbers to the left of the figure are molecular masses in kilodaltons of marker proteins with the indicated mobilities.
|
Strikingly, outer membrane TraVC18S protein appeared to be promiscuous in its ability to form disulfide-linked complexes with other proteins. The lane of the nonreducing gel containing outer membrane protein from the traVC18S mutant (Fig. 2B, lane 3) exhibited a broad smear extending to the top of the gel. This smear was not evident in a reducing gel or in the nonreducing gel containing protein from the traVC10S mutant or the traVC10S/C18S double mutant. It was evident in the lane containing outer membrane protein from traV+ cells (Fig. 2B, lane 1) but to a much lesser degree; in some experiments, this material could be resolved into finely spaced bands near the top of the gel. To determine whether this high-molecular-mass material contained full-length TraV, we isolated it from pOX38 tra+ cell outer membrane by electrophoresis through a 2% agarose gel in sodium dodecyl sulfate gel running buffer. Fractions of this gel corresponding to masses of >172 kDa, which did contain material reactive with anti-TraV antibodies on a Western blot, were then electrophoresed through a 4 to 20% polyacrylamide gradient gel with or without mercaptoethanol. With mercaptoethanol, all of the fractions yielded full-length TraV as shown by Western blotting, with no evidence of degradation products; without mercaptoethanol, immunoreactive material remained at the top of the gel (data not shown). Hence, outer membrane TraV can form disulfide linkages, though most of the wild-type protein was recovered as the monomer after electrophoresis through nonreducing gels (Fig. 2, lanes 1).
Our data indicate that TraV C10 alone is extremely reactive (Fig. 2B, lane 3) but that the presence of C18 reduces C10 reactivity, perhaps by maintaining C10 in C10-C18 intramolecular disulfide linkage. Under this hypothesis, the traVC18S strain might grow poorly because of the accumulation of abnormal protein aggregates formed by disulfide bridges between C10 of outer membrane TraV and cysteine sulfhydryls of other periplasmic proteins.
The internal cysteines of TraV are also required for efficient TraV localization to the outer membrane. We fractionated different strains into periplasmic proteins, cytoplasmic proteins, crude membrane proteins, inner membrane proteins, and outer membrane proteins as described previously (7). As expected (7), wild-type TraV fractionated exclusively with the outer membrane (Fig. 3A). Similar results were obtained with the TraVC10S and TraVC18S mutants (data not shown), except that in the former case, a small amount of TraV fractionated with the inner membrane via sucrose gradient sedimentation (Fig. 3B). In contrast, TraVC10S/C18S was found in all fractions, including shock fluid and soluble (cytoplasmic) material (Fig. 3C). Even so, most protein fractionated with crude membrane, although roughly equal quantities appeared in inner and outer membrane fractions separated by banding in sucrose gradients (9). Thus, for efficient localization of TraV to the outer membrane, either C10 or C18 is required in addition to the N-terminal cysteine characteristic of outer membrane lipoproteins (15), including TraV (3).
|
View larger version (25K): [in a new window] |
FIG. 3. TraV content of different subcellular fractions. Cells were fractionated as described previously (7). WC, whole-cell extract; SF, osmotic shock fluid; C, cytoplasmic proteins; M, crude membranes; IM, purified inner membrane; OM, purified outer membrane. (A) pOX38 traV::cat/pUC traV (wild-type) cells; (B) pOX38 traV::cat/pUC traVC10S cells (membrane fractions only); (C) pOX38 traV::cat/pUC traVC10S/C18S cells.
|
This work was supported by NSF grant MCB 9900553 and funds from the Oklahoma Medical Research Foundation. P.M.S. acknowledges support from the Marjorie Nichlos Chair in Medical Research.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»